| Popis: |
Juan Marco Figueira‐Gonçalves,1,2 Miguel Ángel García-Bello,3,4 Yolanda Ramallo‐Fariña,3– 5 Raúl Méndez,6– 9 Ana Latorre Campos,6,7 Paula González-Jiménez,6,7,9 Germán Peces-Barba,10 María Molina-Molina,11 Pedro Pablo España,12 Estela García,13 Santiago de Jorge Domínguez-Pazos,14 Marta García Clemente,15 Carolina Panadero,16 David de la Rosa-Carrillo,17 Oriol Sibila,18 María Dolores Martínez-Pitarch,19 Nuria Toledo-Pons,20 Cecilia López-Ramirez,21 Wanda Almonte-Batista,22 Abigail Macías-Paredes,23 Diana Badenes-Bonet,24 Eli Nancy Pérez-Rodas,25 Javier Lázaro,26 Sarai Quirós Fernández,27 Rosa Cordovilla,28 Irene Cano-Pumarega,8,29 Antoni Torres,8,18 Rosario Menendez6– 9 On behalf of RECOVID1Pneumology and Thoracic Surgery Service, Unit for Patients with Highly Complex COPD, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain; 2University Institute of Tropical Disease and Public Health of the Canary Islands, University of La Laguna, Santa Cruz de Tenerife, Spain; 3Evaluation Unit (SESCS), Canary Islands Health Research Institute Foundation (FIISC), Tenerife, Spain; 4Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Tenerife, Spain; 5Health Services Research on Chronic Patients Network (REDISSEC), Madrid, Spain; 6Pneumology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; 7Respiratory InFections, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain; 8CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; 9Medicine Department, University of Valencia, Valencia, Spain; 10Pulmonology Department, Hospital Fundación Jiménez Díaz, Madrid, Spain; 11ILD Unit, Respiratory Department, Hospital de Bellvitge, Hospitalet de Llobregat, Spain; 12Respiratory Service, Hospital de Galdakao-Usansolo, Galdakao, Spain; 13Respiratory Service, Hospital de Cabueñes, Gijón, Spain; 14Respiratory Service, Hospital Universitario de A Coruña, A Coruña, Spain; 15Respiratory Service, Hospital Universitario Central de Asturias, Oviedo, Spain; 16Respiratory Service, Hospital de Getafe, Getafe, Spain; 17Respiratory Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 18Respiratory Service, Hospital Clínic, Barcelona, Spain; 19Respiratory Service, Hospital Lluís Alcanyís, Játiva, Spain; 20Respiratory Service, Hospital Son Espases, Palma, Spain; 21Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, Sevilla, Spain; 22Respiratory Service, Hospital de Albacete, Albacete, Spain; 23Respiratory Service, Hospital de Sant Jaume, Calella, Spain; 24Respiratory Service, Hospital del Mar, Barcelona, Spain; 25Respiratory Service, Hospital Municipal de Badalona, Badalona, Spain; 26Respiratory Service, Hospital Royo Villanova, Zaragoza, Spain; 27Respiratory Service, Hospital Basurto, Bilbao, Spain; 28Respiratory Service, Hospital de Salamanca, Salamanca, Spain; 29Respiratory Service, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, SpainCorrespondence: Juan Marco Figueira‐Gonçalves, Pneumology and Thoracic Surgery Service, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain, Tel +34654959246, Email juanmarcofigueira@gmail.comBackground: Chronic obstructive pulmonary disease (COPD) has been associated with worse clinical evolution/survival during a hospitalization for SARS-CoV2 (COVID-19). The objective of this study was to learn the situation of these patients at discharge as well as the risk of re-admission/mortality in the following 12 months.Methods: We carried out a subanalysis of the RECOVID registry. A multicenter, observational study that retrospectively collected data on severe acute COVID-19 episodes and follow-up visits for up to a year in survivors. The data collection protocol includes general demographic data, smoking, comorbidities, pharmacological treatment, infection severity, complications during hospitalization and required treatment. At discharge, resting oxygen saturation (SpO2), dyspnea according to the mMRC (modified Medical Research Council) scale and long-term oxygen therapy prescription were recorded. The follow-up database included the clinical management visits at 6 and 12 months, where re-admission and mortality were recorded.Results: A total of 2047 patients were included (5.6% had a COPD diagnosis). At discharge, patients with COPD had greater dyspnea and a greater need for prescription home oxygen. After adjusting for age, sex and Charlson comorbidity index, patients with COPD had a greater risk of hospital re-admission due to respiratory causes (HR 2.57 [1.35– 4.89], p = 0.004), with no significant differences in survival.Conclusion: Patients with COPD who overcome a serious SARS-CoV2 infection show a worse clinical situation at discharge and a greater risk of re-admission for respiratory causes.Keywords: chronic obstructive pulmonary disease, COPD, COVID-19, coronavirus disease 2019, RECOVID, Spanish COVID-19 registry, SARS-CoV2, severe acute respiratory syndrome coronavirus 2, SEPAR, respiratory failure |
